|  Sign up!  


Return to Course Listing



CME: Current Trends in Management of Blood Glucose in Type 2 Diabetes Mellitus


Program Description / Statement of Need:

In this online CME self-learning program:

Type 2 diabetes mellitus (T2DM), the sixth leading cause of death in the U.S., is directly responsible for more then 73,000 deaths annually and is a contributing factor in more than 220,000 deaths.  More than 20 million Americans have diabetes of which 6 million are undiagnosed.  It is the leading cause of kidney failure and blindness in adults.  Evidence-based guidelines for the management of Type 2 diabetes focus on three areas: lifestyle changes (that include diet, exercise and weight loss); management of cardiovascular disease risk factors (including hypertension, dyslipidemia  and microalbuminuria with the use of aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers); and management of blood glucose levels with pharmacotherapy. 


The Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes identified metformin, insulin and sulfonylureas as first-tier agents and GLP-1 agonist (exenatide) and thiazolidinediones (TZDs or glitazones) as second-tier agents for management of blood glucose levels.  The amylin agonists, alpha-glucosidase inhibitors, glinides and DPP-4 inhibitors were not included in their two tiers of preferred agents, though they may be appropriate choices in selected patients.  Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists and the American College of Endocrinology convened a consensus panel and issued their statement on glycemic control in Type 2 diabetes.  In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain.   Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for the DPP-4 inhibitors and amylin agonists due to impact on weight (DPP-4 – weight neutral; amylin agonists – weight loss) and their lack of hypoglycemia.


Target Audience:

This activity has been designed to meet the educational needs of Physicians, Nurses, Physician Assistants, Nurse Practitioners, Pharmacists and other health care professionals who are interested in managing patients with Type 2 Diabetes Mellitus (T2DM).

Program Objectives:

By the end of the session the participant will be able to:

    • Describe the similarities and differences between the two current treatment algorithms for the management of blood glucose levels in Type 2 diabetes
    • Identify the medications that have a positive or negative impact on weight in each of the treatment algorithms
    • Identify the medications that may cause hypoglycemia in each of the treatment algorithms
    • Recognize the appropriate therapeutic choices in individual patients based on their demographic and clinical characteristics




    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    Release Date: August 20, 2011
    Expiration Date: August 20, 2013

    Faculty: Susan Cornell BS, PharmD, CDE, FAPhA, FAADE

    Faculty Disclosure and Resolution of COI:

    As an provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

    Faculty Disclosure: Susan Cornell, PharmD discloses that she is on the Professional Speaker's Bureau for Johnson & Johnson Diabetes Institute, Novo-Nordisk, Merck, Takeda, and Abbott Diabetes Care.

    She has has performed consulting and/or honoraria received from: Editorial Advisory Board: The Kestrel Diabetes Product Sourcebook, Kestrel Health Information; Advanced Studies in Medicine: Endocrinology Advisory Board, Johns Hopkins;Speaker's Bureau for Johnson & Johnson Diabetes Institute, Novo-Nordisk, Merck, Takeda, and Abbott Diabetes Care.

    Disclosures of Educational Planners: Steven Sachse is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical.

    Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical.

    Commercial Support Disclosure: This program is supported by  educational grants from Daiichi-Sankyo and Merck.


    Viewing Requirements:


    PC Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by Educational Grants from Daiichi-Sankyo and Merck.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.